Open AccessRoxadustat as treatment for a blood transfusion-dependent maintenance hemodialysis patient: A case report and review of literature
Author(s) -
Min Fei,
Xin Wen,
Zhaolan Yu,
Ting Kang,
Weihua Wu,
Santao Ou
Publication year - 2021
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v9.i15.3680
Subject(s) - medicine , hemodialysis , blood transfusion , intensive care medicine , surgery
Erythropoiesis-stimulating agents (ESAs) have revolutionized the therapeutic strategy for anemia in chronic kidney disease. However, some cases are resistant or hyporesponsive to ESAs. Roxadustat is an oral hypoxia-inducible factor-prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism. Here, we describe a hemodialysis patient with refractory anemia who did not respond to traditional treatments and depended on blood transfusion for more than 1 year. After applying Roxadustat, the patient's anemia improved significantly.